These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31524535)

  • 21. Clinical trials of eicosapentaenoic acid (EPA) prescription products for the treatment of hypertriglyceridemia.
    Doggrell SA
    Expert Opin Pharmacother; 2019 Jul; 20(10):1221-1225. PubMed ID: 31038369
    [No Abstract]   [Full Text] [Related]  

  • 22. Defining the Role of Icosapent Ethyl in Clinical Practice.
    Chatterjee S; Hajra A; Bandyopadhyay D; Ghosh RK; Deedwania PC
    Am J Cardiovasc Drugs; 2020 Dec; 20(6):517-524. PubMed ID: 32157567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
    Kedia AW; Lynch E
    Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies.
    Bays HE; Ballantyne CM; Doyle RT; Juliano RA; Philip S
    Prostaglandins Other Lipid Mediat; 2016 Sep; 125():57-64. PubMed ID: 27418543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Gregson J; Pocock SJ; Ballantyne CM;
    J Am Coll Cardiol; 2019 Jun; 73(22):2791-2802. PubMed ID: 30898607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
    Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN
    Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions.
    Hussain A; Ballantyne CM; Saeed A; Virani SS
    Curr Atheroscler Rep; 2020 Jun; 22(7):25. PubMed ID: 32494924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides.
    Pareek M; Mason RP; Bhatt DL
    Expert Opin Drug Saf; 2022 Jan; 21(1):31-42. PubMed ID: 34253137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).
    Braeckman RA; Manku MS; Bays HE; Stirtan WG; Soni PN
    Prostaglandins Leukot Essent Fatty Acids; 2013 Sep; 89(4):195-201. PubMed ID: 23992935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
    Gaba P; Bhatt DL; Giugliano RP; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Tardif JC; Ballantyne CM; Pinto DS; Budoff MJ; Gibson CM
    J Am Coll Cardiol; 2021 Oct; 78(15):1525-1537. PubMed ID: 34620410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.
    Bays HE; Ballantyne CM; Braeckman RA; Stirtan WG; Soni PN
    Am J Cardiovasc Drugs; 2013 Feb; 13(1):37-46. PubMed ID: 23325450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isosapent ethyl (Vascepa) for severe hypertriglyceridemia.
    Med Lett Drugs Ther; 2013 Apr; 55(1415):33-4. PubMed ID: 23836343
    [No Abstract]   [Full Text] [Related]  

  • 33. Catch of the Day: Icosapent Ethyl for Reducing Cardiovascular Risk.
    Dixon DL
    Am J Med; 2020 Jul; 133(7):802-804. PubMed ID: 32243872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study).
    Ballantyne CM; Braeckman RA; Bays HE; Kastelein JJ; Otvos JD; Stirtan WG; Doyle RT; Soni PN; Juliano RA
    J Clin Lipidol; 2015; 9(3):377-83. PubMed ID: 26073397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis.
    Arbel R; Aboalhasan E; Hammerman A; Azuri J
    Am J Med; 2021 Jul; 134(7):e415-e419. PubMed ID: 33450273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction.
    Boden WE; Baum S; Toth PP; Fazio S; Bhatt DL
    Future Cardiol; 2021 Jan; 17(1):155-174. PubMed ID: 32959713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
    Bazarbashi N; Miller M
    Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
    Crandell JR; Tartaglia C; Tartaglia J
    Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT.
    Gaba P; Bhatt DL; Mason RP; Miller M; Verma S; Steg PG; Boden WE;
    J Clin Lipidol; 2022; 16(4):389-402. PubMed ID: 35773147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Icosapent ethyl for hypertriglyceridaemia and atherosclerosis: greater RESPECT for increased therapeutic use.
    Gaba P; Bhatt DL; Boden WE
    Eur Heart J; 2024 Feb; 45(6):439-442. PubMed ID: 37889071
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.